Renaissance Technologies LLC
- SEC CIK
- 0001037389
- Latest filing
- Aug 13, 2026
RNTX holding history
Rein Therapeutics, Inc. in every 13F filed by Renaissance Technologies LLC, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
RNTX overviewAll 13F holders of RNTXFull Q2 2026 holdings
- Shares (Q2 2026)
- 19,000
- Value
- $19.8K
- % of portfolio
- <0.1%
- Quarters held
- 19
- Since Q1 2021
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q2 2026 | 19,000 | $19.8K | <0.1% | −5,500−22.4% | Reduced | Holders |
| Q1 2026 | 24,500 | $31.9K | <0.1% | +1,800+7.9% | Added | Holders |
| Q4 2025 | 22,700 | $26.3K | <0.1% | +4,402+24.1% | Added | Holders |
| Q3 2025 | 18,298 | $21.0K | <0.1% | +18,298 | New | Holders |
| Q4 2024 | 0 | $0 | 0.0% | −13,164−100.0% | Sold out | Holders |
| Q3 2024 | 13,164 | $46.6K | <0.1% | −11,700−47.1% | Reduced | Holders |
| Q2 2024 | 24,864 | $68.9K | <0.1% | −20,200−44.8% | Reduced | Holders |
| Q1 2024 | 45,064 | $299.0K | <0.1% | +17,045+60.8% | Added | Holders |
| Q4 2023 | 28,019 | $85.0K | <0.1% | +9,055+47.7% | Added | Holders |
| Q3 2023 | 18,964 | $29.0K | <0.1% | +3,100+19.5% | Added | Holders |
| Q2 2023 | 15,864 | $28.0K | <0.1% | +3,200+25.3% | Added | Holders |
| Q1 2023 | 12,664 | $16.0K | <0.1% | +2,100+19.9% | Added | Holders |
| Q4 2022 | 10,564 | $25.0K | <0.1% | +1,029+10.8% | AddedConverted for a 1-for-20 split | Holders |
| Q3 2022 | 190,691 | $39.0K | <0.1% | +75,500+65.5% | Added | Holders |
| Q2 2022 | 115,191 | $30.0K | <0.1% | +56,691+96.9% | Added | Holders |
| Q1 2022 | 58,500 | $30.0K | <0.1% | −411,940−87.6% | Reduced | Holders |
| Q4 2021 | 470,440 | $265.0K | <0.1% | −264,281−36.0% | Reduced | Holders |
| Q3 2021 | 734,721 | $749.0K | <0.1% | −296,407−28.7% | Reduced | Holders |
| Q2 2021 | 1,031,128 | $1.29M | <0.1% | −219,372−17.5% | Reduced | Holders |
| Q1 2021 | 1,250,500 | $1.79M | <0.1% | – | – | Holders |
Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.